[Peng, Qing-Hua] Hunan Univ Tradit Chinese Med, Affiliated Hosp 1, Dept Ophthalmol, Changsha 410007, Hunan, Peoples R China.
dry;eye;LACRIMAL;GLAND;EXTRACT;of;buddleja;OFFICINALIS;ANDROGEN;dry eye;lacrimal gland;extract of buddleja officinalis;androgen
AIM: To assess the effects of extract of Buddleja officinalis on tear secretion volume, tear film stability, expressions of TGF-beta 1, IL-1 beta, TNF-alpha in lacrimal gland of castrated rabbits with dry eye. METHODS: A total of 30 victory rabbits were divided averagely into normal group (A), model group (B), therapy group with low dose extract of Buddleja officinalis (C), therapy group with high dose extract of Buddleja officinalis (D) and therapy group with genistein (E). The dry eye model was established with orchiectomy on Group B, C, D, E. Group C, D, E were administered intragastrically with corresponding dose extract of Buddleja officinalis or genistein for 30 days. All rabbits were detected with SIT. TGF-beta 1, IL-1 beta, TNF-alpha were detected with immunohistochemistry and the ultrastructure of lacrimal gland was observed under transmission electron microscope. RESULTS: The SIT value of group C, D, E were respectively 13.167 +/- 4.957, 14.667 +/- 5.279, 8.667 +/- 0.516, obviously higher than that of group B 5.667 +/- 2.338 (P<0.01). The positive expression of IL-1 beta in acinar cell and glandular tube cell of group C, D were 0.470 +/- 0.048, 0.510 +/- 0.088, obviously lower than that of group B 0.770 +/- 0.118 (P <0.01). The positive expression of TNF-alpha of group C, D were 0.498 +/- 0.156, 0.435 +/- 0.069, obviously lower than that of group B 0.769 +/- 0.095 too (P <0.01). The positive expression of TGF-beta 1 of group C, D were 0.406 +/- 0.171, 0.497 +/- 0.147, obviously higher than that of group B 0.222 +/- 0.113(P<0.01). Any result of group C, D was positive compared with that of group E (P <0.05). Ultrastructure of the lacrimal gland of group C, D, E was well preserved, especially in D group it was remarkable. CONCLUSION: The extract of Buddleja officinalis can adjust lacrimal gland partial inflammation of dry eye.
AIM: To explore the effect of Qingguangan on the expressions of MMP-2 and MMP-9 in filtering bleb scarring area after trabeculectomy in rabbit model. METHODS: Thirty-two New Zealand rabbits were randomized into four groups: control group, experimental group, MMC group (ocular trabeculectomy in combination with MMC), and Qingguangan group. Trabeculectomy was performed on both eyes in each group except control group. Qingguangan group was mouth-fed with Qingguangan (solution). On postoperative day 14, the appearances of MMP-2 and MMP-9 on filtrating blebs were observed by immunohistochemistry. RESULTS: Statistical differences of the expressions of MMP-2 and MMP-9 were noted among groups on day 14 following surgery. Histology immunohistochemistry showed significant differences on the expressions of MMP-2 and MMP-9 between each groups( P<0.05). CONCLUSION: Qingguangan can promote the expressions of MMP-2 and MMP-9.
• AIM: To explore the effect of Buddleia flavonoids drugcontaining plasma and androgen receptor(AR) blocker on the expression of STAT1 phosphoprotein. • METHODS: In vitro lacrimal gland epithelial cells were cultivated with H2 O2 to establish the dry eye apoptosis state. Blank plasma group, Buddleia officinalis plasma total flavonoids interfere with drug-containing group, and the intervention group of testosterone propionate were set. The expressions of STAT1 phosphoprotein of each group were observed by Western blot and AR blocker flutamide was used to explore the intended androgen effect of Buddleia flavonoids. • RESULTS: After the intervention of drug-containing plasma, the expression of STAT1 Phosphoprotein in Buddleja officinalis drug-containing plasma intervention group ( 0. 353 ± 0. 494 ) and testosterone propionate intervention group (0.502 ± 0.036) were enhanced and the differences between the two groups were significant ( P < 0.01). After using the AR blocker in all groups, the expression of STAT1 phosphoprotein in each group (0. 268 ± 0. 061, 0. 283 ± 0. 106, 0. 213 ± 0. 071 ) had no difference. • CONCLUSION: Buddleja officinalis drug-containing plasma total flavonoids can promote the expression of STAT1 phosphorylation.
OBJECTIVE: To explore the possible mechanism of eye drops of Buddleja officinalis extract in treating dry eye of castrated rats by analyzing the expressions of Bax and Bcl-2 proteins. METHODS: Forty-five Wistar male rats were randomly divided into sham-operated group, untreated group and eye drops of Buddleja officinalis Maxim. extract (treatment) group. The dry eye model was established with orchiectomy in the untreated group and treatment group. Rats in the treatment group were treated with eye drops of Buddleja officinalis Maxim. extract, one drop once, three times daily. Eyes of rats in the sham-operated group and untreated group were instilled with normal saline. After one-, two-, or three-month treatment, five rats in each group were scarified respectively. Then samples were taken to detect related indices. Expressions of Bax and Bcl-2 of lacrimal gland were checked by immunohistochemical method and quantity of apoptotic cells was counted. RESULTS: After one-, two- or three-month treatment, the quantities of expressions of Bax in acinar epithelial cells and glandular tube cells were significantly lower, and those of Bcl-2 were significantly higher in the treatment group than in the untreated group, and the quantities of apoptotic cells of the treatment group were significantly lower than those of the untreated group (P<0.01). CONCLUSION: The main components of extract of Buddleja officinalis Maxim. are flavonoids, which can significantly inhibit cell apoptosis in lacrimal gland.
Glaucoma, the second leading cause of blindness, is an irreversible optic neuropathy. The mechanism of optic nerve injury caused by glaucoma is undefined at present. There is no effective treatment method for the injury. Stem cells have the capacity of self-renewal and differentiation. These two features have made them become the research focus on improving the injury at present. This paper reviews the application progress on different types of stem cells therapy for optic nerve injury caused by glaucoma.